Top

World Journal of Urology

Published in:

01-04-2014 | Original Article

The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy

Authors: Lionel L. Bañez, Simone Albisinni, Stephen J. Freedland, Andrea Tubaro, Cosimo De Nunzio

Published in: World Journal of Urology | Issue 2/2014

Abstract

Purpose

Obese men have been reported to have lower serum PSA values relative to normal-weight men in population-based studies, screening cohorts, and in men with prostate cancer (CaP) treated with surgery. There are concerns that PSA may be less accurate in detecting prostate cancer in men with increased body mass index (BMI). We determine whether the diagnostic potential of PSA is negatively influenced by obesity by comparing its operating characteristics across BMI categories among men undergoing prostate biopsy.

Methods

Demographic, clinical, and histopathological data on 917 men who underwent trans-rectal ultrasound-guided prostate needle biopsy from 2002 to 2010 at a University hospital in Italy were used in the study. Men were categorized for BMI as follows: <25 kg/m² (normal weight), 25–29.9 kg/m² (overweight), and ≥30 kg/m² (obese). Receiver operator characteristics (ROC) curves were used to assess PSA accuracy for predicting prostate cancer overall and then stratified according to digital rectal examination (DRE) findings using the area under the ROC curve (AUC).

Results

The obesity rate of the study cohort was 21 %. There was no statistically significant difference in the overall AUCs of PSA for predicting CaP among normal-weight (AUC = 0.56), overweight (AUC = 0.60), and obese men (AUC = 0.60; p = 0.68) in either DRE-positive or negative men.

Conclusions

In a cohort of Italian men undergoing prostate biopsy, the performance accuracy of PSA as a predictor of CaP is not significantly altered by BMI. Obesity does not negatively impact the overall ability of PSA to discriminate between CaP and benign conditions.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138 PubMedCrossRef

Bosetti C, Bertuccio P, Chatenoud L, Negri E, La Vecchia C, Levi F (2011) Trends in mortality from urologic cancers in Europe, 1970–2008. Eur Urol 60(1):1–15. doi:10.1016/j.eururo.2011.03.047 PubMedCrossRef

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90. doi:10.3322/caac.20107 PubMedCrossRef

Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348(17):1625–1638. doi:10.1056/NEJMoa021423 PubMedCrossRef

Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ (2001) Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 10(4):345–353PubMed

Buschemeyer WC 3rd, Freedland SJ (2007) Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52(2):331–343. doi:10.1016/j.eururo.2007.04.069 PubMedCrossRef

Freedland SJ, Grubb KA, Yiu SK, Nielsen ME, Mangold LA, Isaacs WB, Epstein JI, Partin AW (2005) Obesity and capsular incision at the time of open retropubic radical prostatectomy. J Urol 174 (5): 1798–1801; discussion 1801. doi:10.1097/01.ju.0000177077.53037.72

Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, Wang Y, Terris MK, Aronson WJ, Presti JC Jr, Kane CJ, Amling CL, Moul JW, Freedland SJ (2007) Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 298(19):2275–2280. doi:10.1001/jama.298.19.2275 PubMedCrossRef

Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, Higgins B, Lynch S, Rozanski T, Troyer D, Thompson I (2005) The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103(5):1092–1095. doi:10.1002/cncr.20856 PubMedCrossRef

10.

Barqawi AB, Golden BK, O’Donnell C, Brawer MK, Crawford ED (2005) Observed effect of age and body mass index on total and complexed PSA: analysis from a national screening program. Urology 65(4):708–712. doi:10.1016/j.urology.2004.10.074 PubMedCrossRef

11.

Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, Wener M (2007) Obesity is negatively associated with prostate-specific antigen in US men, 2001–2004. Cancer Epidemiol Biomarkers Prev 16(1):70–76. doi:10.1158/1055-9965.EPI-06-0588 PubMedCrossRef

12.

Fowke JH, Motley SS, Cookson MS, Concepcion R, Chang SS, Wills ML, Smith JA Jr (2007) The association between body size, prostate volume and prostate-specific antigen. Prostate Cancer Prostatic Dis 10(2):137–142. doi:10.1038/sj.pcan.4500924 PubMedCrossRef

13.

Grubb RL 3rd, Black A, Izmirlian G, Hickey TP, Pinsky PF, Mabie JE, Riley TL, Ragard LR, Prorok PC, Berg CD, Crawford ED, Church TR, Andriole GL Jr (2009) Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 18(3):748–751. doi:10.1158/1055-9965.EPI-08-0938 PubMedCrossRef

14.

Beebe-Dimmer JL, Faerber GJ, Morgenstern H, Werny D, Wojno K, Halstead-Nussloch B, Cooney KA (2008) Body composition and serum prostate-specific antigen: review and findings from Flint Men’s Health Study. Urology 71(4):554–560. doi:10.1016/j.urology.2007.11.049 PubMedCentralPubMedCrossRef

15.

Chang IH, Ahn SH, Han JH, Kim TH, Kim YS, Myung SC (2009) The clinical significance in healthy men of the association between obesity related plasma hemodilution and tumor marker concentration. J Urol 181(2): 567–572; discussion 572–563. doi:10.1016/j.juro.2008.10.030

16.

Lopez Fontana C, Maselli ME, Perez Elizalde R, Di Milta N, Corica Alberto P, Lopez Laur JD (2011) Obesity modifies prostatic specific antigen in men over 45 years. Arch Esp Urol 64(1):35–42PubMed

17.

Ando R, Nagaya T, Hashimoto Y, Suzuki S, Itoh Y, Umemoto Y, Ikeda N, Tozawa K, Kohri K, Tokudome S (2008) Inverse relationship between obesity and serum prostate-specific antigen level in healthy Japanese men: a hospital-based cross-sectional survey, 2004–2006. Urology 72(3):561–565. doi:10.1016/j.urology.2008.04.008 PubMedCrossRef

18.

Kubota Y, Seike K, Maeda S, Shinohara Y, Iwata M, Sugimoto N (2011) Relationship between prostate-specific antigen and obesity in prostate cancer screening: analysis of a large cohort in Japan. Int J Urol 18(1):72–75. doi:10.1111/j.1442-2042.2010.02667.x PubMedCrossRef

19.

De Nunzio C, Trucchi A, Miano R, Stoppacciaro A, Fattahi H, Cicione A, Tubaro A (2009) The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol 181(3): 1069–1074; discussion 1074–1065. doi:10.1016/j.juro.2008.10.163

20.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL (2005) The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29(9):1228–1242PubMedCrossRef

21.

Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA, O’Brien B, Clapp JD, Rathmell JM, Riley TL, Hayes RB, Kramer BS, Izmirlian G, Miller AB, Pinsky PF, Prorok PC, Gohagan JK, Berg CD (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319. doi:10.1056/NEJMoa0810696 PubMedCentralPubMedCrossRef

22.

Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328. doi:10.1056/NEJMoa0810084 PubMedCrossRef

23.

Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV (2011) The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev 20(3):501–508. doi:10.1158/1055-9965.EPI-10-1006 PubMedCentralPubMedCrossRef

24.

Chavarro JE, Toth TL, Wright DL, Meeker JD, Hauser R (2010) Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 93(7):2222–2231. doi:10.1016/j.fertnstert.2009.01.100 PubMedCentralPubMedCrossRef

25.

De Nunzio C, Miano R, Trucchi A, Finazzi Agro E, Tubaro A (2008) Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol 4(12):1561–1568. doi:10.1517/17425250802587058 PubMedCrossRef

26.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr (2006) Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98(16):1128–1133. doi:10.1093/jnci/djj307 PubMedCrossRef

27.

Bañez LL, Sun L, Trock BJ, Han M, Partin AW, Aronson WJ, Terris MK, Presti JC, Jr., Kane CJ, Amling CL, Moul JW, Freedland SJ (2009) Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. J Urol 182 (2):491–496; discussion 496–498. doi:10.1016/j.juro.2009.04.007

28.

Loeb S, Carter HB, Schaeffer EM, Ferrucci L, Kettermann A, Metter EJ (2009) Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging. J Urol 182(6):2646–2651. doi:10.1016/j.juro.2009.08.041 PubMedCrossRef

29.

Rundle A, Neugut AI (2008) Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68(4):373–380. doi:10.1002/pros.20704 PubMedCrossRef

30.

Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM (2010) Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology 76 (5):1268 e1261–e1266. doi:10.1016/j.urology.2010.04.060

Title: The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy
Authors: Lionel L. Bañez
Simone Albisinni
Stephen J. Freedland
Andrea Tubaro
Cosimo De Nunzio
Publication date: 01-04-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 2/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-012-0919-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2014

Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses

The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy

Expression of β-tubulin isotypes in urothelial carcinoma of the bladder

Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival

Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study

Prostate cancer detection rates in different biopsy schemes. Which cores for which patients?